Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Laryngoscope. 2021 Dec;131(12):2674-2683. doi: 10.1002/lary.29689. Epub 2021 Jun 18.
OBJECTIVES/HYPOTHESIS: The tumor immune microenvironment in temporal bone squamous cell carcinoma (TBSCC), including the programmed death-ligand 1 (PD-L1) expression and tumor-infiltrating lymphocytes (TILs), has not been established.
Retrospective cohort study.
We performed immunohistochemistry analyses to retrospectively analyze 123 TBSCC cases for PD-L1 expression and TILs and their prognostic significance. We also evaluated the prognostic correlations between these immunomarkers and the therapeutic responses to chemoradiotherapy (CRT).
PD-L1 expression (≥1%) was detected in 62 (50.4%) TBSCC cases and was significantly associated with worse prognosis: progression-free survival (PFS), P < .0001; overall survival (OS), P = .0009. A high density of CD8 TILs was significantly associated with better prognosis (PFS, P = .0012; OS, P = .0120). In contrast, a high density of Foxp3 TILs tended to be associated with an unfavorable prognosis (PFS, P = .0148; OS, P = .0850). With regard to the tumor microenvironment subtypes defined by CD8 TILs and PD-L1 expression, the CD8 /PD-L1 group showed significantly worse prognosis. Among the 36 neoadjuvant CRT-treated cases, PD-L1 expression was significantly associated with worse OS (P = .0132). Among the 32 CRT-treated cases without surgery, a high density of CD8 TILs tended to be more highly associated with complete response to CRT compared to a low density of CD8 TILs (P = .0702).
These results indicate that the evaluation of the tumor immune microenvironment may contribute to the prediction of prognoses and the selection of an individualized therapeutic strategy for patients with TBSCC.
4 Laryngoscope, 131:2674-2683, 2021.
目的/假设:颞骨鳞状细胞癌(TBSCC)的肿瘤免疫微环境,包括程序性死亡配体 1(PD-L1)表达和肿瘤浸润淋巴细胞(TILs),尚未确定。
回顾性队列研究。
我们通过免疫组织化学分析,对 123 例 TBSCC 病例进行 PD-L1 表达和 TILs 的回顾性分析,并评估其预后意义。我们还评估了这些免疫标志物与放化疗(CRT)治疗反应之间的相关性。
62 例(50.4%)TBSCC 病例检测到 PD-L1 表达(≥1%),与较差的预后显著相关:无进展生存期(PFS),P < .0001;总生存期(OS),P = .0009。CD8 TILs 高密度与较好的预后显著相关(PFS,P = .0012;OS,P = .0120)。相反,Foxp3 TILs 高密度倾向于与不良预后相关(PFS,P = .0148;OS,P = .0850)。根据 CD8 TILs 和 PD-L1 表达定义的肿瘤微环境亚型,CD8 /PD-L1 组显示出明显较差的预后。在 36 例新辅助 CRT 治疗的病例中,PD-L1 表达与较差的 OS 显著相关(P = .0132)。在 32 例未手术的 CRT 治疗病例中,与 CD8 TILs 密度低相比,CD8 TILs 密度高与 CRT 完全缓解的相关性更高(P = .0702)。
这些结果表明,评估肿瘤免疫微环境可能有助于预测 TBSCC 患者的预后,并为个体化治疗策略的选择提供依据。
4 级 Laryngoscope,131:2674-2683,2021。